193 related articles for article (PubMed ID: 22729361)
1. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.
Yokoyama T; Enomoto T; Serada S; Morimoto A; Matsuzaki S; Ueda Y; Yoshino K; Fujita M; Kyo S; Iwahori K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2013 Jan; 132(2):472-84. PubMed ID: 22729361
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
3. The Expression of BTS-2 Enhances Cell Growth and Invasiveness in Renal Cell Carcinoma.
Pham QT; Oue N; Yamamoto Y; Shigematsu Y; Sekino Y; Sakamoto N; Sentani K; Uraoka N; Tiwari M; Yasui W
Anticancer Res; 2017 Jun; 37(6):2853-2860. PubMed ID: 28551621
[TBL] [Abstract][Full Text] [Related]
4. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
[TBL] [Abstract][Full Text] [Related]
5. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer.
Fang KH; Kao HK; Chi LM; Liang Y; Liu SC; Hseuh C; Liao CT; Yen TC; Yu JS; Chang KP
Laryngoscope; 2014 Sep; 124(9):E354-60. PubMed ID: 24706327
[TBL] [Abstract][Full Text] [Related]
7. Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study.
Chiang SF; Kan CY; Hsiao YC; Tang R; Hsieh LL; Chiang JM; Tsai WS; Yeh CY; Hsieh PS; Liang Y; Chen JS; Yu JS
Dis Markers; 2015; 2015():874054. PubMed ID: 26494939
[TBL] [Abstract][Full Text] [Related]
8. The expression of BST2 in human and experimental mouse brain tumors.
Wainwright DA; Balyasnikova IV; Han Y; Lesniak MS
Exp Mol Pathol; 2011 Aug; 91(1):440-6. PubMed ID: 21565182
[TBL] [Abstract][Full Text] [Related]
9. BST2, a Novel Inhibitory Receptor, Is Involved in NK Cell Cytotoxicity through Its Cytoplasmic Tail Domain.
Oh J; Yi E; Jeong SK; Park S; Park SH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232695
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
12. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R
Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760
[TBL] [Abstract][Full Text] [Related]
13. Metabolic vulnerabilities in endometrial cancer.
Byrne FL; Poon IK; Modesitt SC; Tomsig JL; Chow JD; Healy ME; Baker WD; Atkins KA; Lancaster JM; Marchion DC; Moley KH; Ravichandran KS; Slack-Davis JK; Hoehn KL
Cancer Res; 2014 Oct; 74(20):5832-45. PubMed ID: 25205105
[TBL] [Abstract][Full Text] [Related]
14. Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells.
Sayeed A; Luciani-Torres G; Meng Z; Bennington JL; Moore DH; Dairkee SH
PLoS One; 2013; 8(6):e67191. PubMed ID: 23840623
[TBL] [Abstract][Full Text] [Related]
15. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
16. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
17. CD48 as a novel molecular target for antibody therapy in multiple myeloma.
Hosen N; Ichihara H; Mugitani A; Aoyama Y; Fukuda Y; Kishida S; Matsuoka Y; Nakajima H; Kawakami M; Yamagami T; Fuji S; Tamaki H; Nakao T; Nishida S; Tsuboi A; Iida S; Hino M; Oka Y; Oji Y; Sugiyama H
Br J Haematol; 2012 Jan; 156(2):213-24. PubMed ID: 22098460
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
[TBL] [Abstract][Full Text] [Related]
19. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-760 inhibits cell viability and migration through down-regulating BST2 in gastric cancer.
Liu W; Li Y; Feng S; Guan Y; Cao Y
J Biochem; 2020 Aug; 168(2):159-170. PubMed ID: 32167539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
